AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
1902 MAR 28 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - Scientists in Japan say the intratumoral balance between a key angiogenic growth factor and a soluble form of its receptor may predict outcomes in breast cancer.
A recent study of more than 100 breast cancers has shed new light on the role the growth factor and receptor may play in cancer progression.
"Soluble vascular endothelial growth factor receptor-1 (sVEGFR1), a naturally occurring soluble form of VEGFR1, is a negative counterpart of the vascular endothelial growth factor (VEGF) signaling pathway, which has been characterized as one of the most important endothelial regulators in human tumor angiogenesis," said Masakazu Toi and coauthors, who work in the Breast Unit at Tokyo Metropolitan Komagome Hospital in Japan.
The investigators said at least 85% of the 110 tumors they examined contained 0.1 ng/mg or more of sVEGFR1 protein. There was a significant correlation between the amount of sVEGFR1 and the amount of VEGF present in breast cancer tissues, but there was no correlation with other factors such as "age, menopause status, lymph node involvement, or hormone receptor status," they noted.
Initially, univariate analysis placed greater emphasis on the importance of VEGF for predicting progression, but the numbers changed when investigators combined their data.
"In the combined analysis, the ratio of sVEGFR1 and VEGF levels provided more statistically significant prognostic value ...